SUMMARY
Over the years, the issues of clinical course and seborrheic dermatitis treatment in children and adults are actual. This is evidenced by numerous publications of domestic and foreign scientists. Seborrheic dermatitis occurs in 20-25 % of the population aged 16 to 35 years, the disease is more common in men than in women, which is associated with androgenic stimulation of the sebaceous glands. The cause of seborrheic dermatitis is the fungus Malassezia, and factors that contribute to the development of this disease are: endocrine pathology, neurological diseases, immunodeficiency, genetic predisposition, hyperhidrosis, vitamin deficiency, the effects of alkaline detergents on the skin and other. The correction of seborrheic dermatitis of the scalp is a complex process that must be comprehensive: to eliminate not only the symptoms, but also to effect on the causes of the disease. In the pharmaceutical market ofUkraine, the number of combined drugs used for the treatment and prevention of seborrheic dermatitis is quite limited. Because of that it is important to develop a new drug in the form of shampoo for the prevention and treatment of this hair disease.Conclusions. The results of the study indicated the absence of toxic effects of the new drug (according to the classification of K. K. Sidorov belongs to the IV class of toxicity – low-toxic substances), as well as local irritation in the applied to the skin and mucous membranes of the eye. The new drug in the form of shampoo under the conditions of model pathology showed pronounced antialterative and reparative activity.